On National Viagra Day, Women Finally Claim Their Turn:

Stock Information for Dare Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dare Bioscience Inc.

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
Daré Bioscience Participates in Virtual Investor "What This Means" Segment
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Telehealth Now Available for DARE to PLAY(TM) Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
DARE to PLAY(TM) Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.